comparemela.com

Michel Pairet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Boehringer Ingelheim agrees $2bn siRNA therapeutic collaboration

Boehringer Ingelheim agrees $2bn siRNA therapeutic collaboration
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Michel pairetZicai liangBoehringer ingelheimRibo life sciencesSuzhou ribo life science coRibocure pharmaceuticals ab riboRibocure pharmaceuticalsSenior vice presidentGlobal headCardiometabolic diseases researchInnovation unitManaging directors

Boehringer Ingelheim announces acquisition of T3 Pharmaceuticals

Boehringer Ingelheim has announced the acquisition of Switzerland-based biotech company T3 Pharmaceuticals in a deal valued at up to CHF450m ($509m).

Simon ittigMichel pairetBoehringer ingelheimUniversity of baselIngelheim boardManaging directors

Boehringer Ingelheim expands immunooncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Boehringer Ingelheim today announced the acquisition of privatelyheld T3 Pharmaceuticals AG T3 Pharma a clinical stage Swiss biotech company for an amount of up to 450 million CHF.

Switzerland generalBoehringer ingelheimEngagers tcesSimon ittigMichel pairetBoehringer ingelheim venture fundT cell engagersManaging directorsMedia contactTen woldeMedia relationsBoehringer ingelheim immunooncology t3 pharmaceuticals ag pharma cancer treatment michel pairet simon ittig venture fund acquisition

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer .

Switzerland generalMichel pairetSimon ittigBoehringer ingelheimEngagers tcesUniversity of baselBoehringer ingelheim venture fundAnimal healthT cell engagersManaging directorsHuman pharmaPreference capitalWille finance

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Michel pairetSimon ittigBoehringer ingelheimUniversity of baselInnovation unitCovant therapeutics

vimarsana © 2020. All Rights Reserved.